Engineering of rare, naturally occurring non-developable antibodies into powerful therapeutics
Rare antibodies with unusual structures and ultra-long CDRs have the potential to bind to difficult-to-access epitopes (e.g., GPCRs, ion channels), and thus offer a unique mode of action. But since they are considered non-developable, they are often excluded from rationally designed antibody libraries or neglected in developability-driven AI selections. This application note demonstrates how tailored […]
Automated customized antibody purification with flowbot ONE
Automating small-scale purification, e.g., of antibodies, can enable more research, shorten workflows, free up time for other tasks, and standardize results. This application note by flow robotics demonstrates the development of an automated purification solution for human IgG samples (YUMAB) using the flowbot® ONE* and PhyTip® columns. Read more
Discovery of a neutralizing antibody to treat covid-19
THE NEEDA number of therapeutic options have been explored over the course of the COVID-19 pandemic, yet there is still no effective treatment for hospitalized patients. It istherefore crucial to identify targets for antiviral intervention and elucidate critical viraland host determinants that play a central role in the development of severe disease. THE SOLUTIONFast track […]
Discovery of a therapeutic antibody for the treatment of inflammatory bowel disease and type I diabetes
In cooperation with Enthera, YUMAB generated Ent001, a stabilized IgG4, without the need for bioinformatic engineering to reach an affinity to TMEM in the lower pM range. Ent001 specifically binds to TMEM219 inhibiting its interaction with IGFBP3. With the lead antibody Ent001 YUMAB enabled Enthera to conduct successful preclinical development studies and to proceed with […]
